This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
JDRF ISPAD fellowship 2019


Kalie Tommerdahl

was awarded the ISPAD JDRF Fellowship for 2019

Kalie L. Tommerdahl, MD, is a fellow in Pediatric Endocrinology and Diabetes at Children’s Hospital Colorado and the Barbara Davis Center for Diabetes in Aurora, Colorado, USA.  She received her medical education at Northwestern University’s Feinberg School of Medicine and completed her residency training in Pediatrics at Nationwide Children’s Hospital in Columbus, Ohio, USA.  During fellowship, Dr. Tommerdahl was invited to be an investigator for the Effects of MEtformin on CardiovasculaR Function in AdoLescents with Type 1 Diabetes (EMERALD) clinical trial where she evaluated the cardiovascular and metabolic impact of obesity on youth with type 1 diabetes as compared to youth with type 2 diabetes as well as the renal, inflammatory, and mitochondrial effects of metformin on youth with type 1 diabetes. 

Dr. Tommerdahl is the principal investigator of a study entitled “MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth with Type 1 Diabetes Mellitus (MERMAID-T1D)” which received the ISPAD-JDRF fellowship.  This project aims to assess insulin sensitivity, body composition, markers of cardiometabolic function, and markers of kidney function prior to and following initiation of two automated insulin delivery systems: the hybrid closed loop artificial pancreas and the predictive low glucose suspend system.  Dr. Tommerdahl hypothesizes that pauses in insulin delivery secondary to the use of automated insulin delivery systems will result in the improvement of insulin sensitivity, cardiometabolic function, and renal function in youth with type 1 diabetes.  She aims to develop strategies to advance and optimize the use of technology in the management of all forms of diabetes with the goal of improving the cardiometabolic and renal risk factors of diabetes, the leading causes of morbidity and mortality in this disease.       

Contact Us

ISPAD Executive Office
c/o K.I.T. Group GmbH
Association & Conference Management
Kurfürstendamm 71
10709 Berlin, Germany


Click the link below to join the Society!

Join Today!

Phone: +49 (0)30 24603-210
Fax: +49 (0)30 24603-200
Email: secretariat@ispad.or

Privacy Policy
Terms of Service
Legal Notice    


 © 2020 International Society for Pediatric and Adolescent Diabetes (ISPAD)

Association Management Software Powered by YourMembership  ::  Legal